Fredag 14 Mars | 08:00:42 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-26 13:00 Bokslutskommuniké 2025
2025-08-21 13:00 Kvartalsrapport 2025-Q2
2025-06-27 N/A X-dag ordinarie utdelning 2CUREX 0.00 SEK
2025-06-26 N/A Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 - Årsstämma
2024-02-22 - Bokslutskommuniké 2023
2023-11-23 - Kvartalsrapport 2023-Q3
2023-11-14 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-29 - Kvartalsrapport 2023-Q1
2023-05-26 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 - Årsstämma
2023-02-23 - Bokslutskommuniké 2022
2023-02-10 - Extra Bolagsstämma 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 - Årsstämma
2021-05-27 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-07-02 - Extra Bolagsstämma 2020
2020-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 - Årsstämma
2020-05-28 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-22 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 - Årsstämma
2019-05-17 - Kvartalsrapport 2019-Q1
2019-04-02 - Extra Bolagsstämma 2019
2019-03-01 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 - Årsstämma
2018-05-18 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamt inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2021-12-22 08:45:00

2cureX, Leader in Oncology Drug Sensitivity Testing, announced today that the company has received its first order for an IndiTreat® product. This milestone has been long expected as it signals the start of a new stage for IndiTreat®. The order, small but of strategic importance, was placed by Labormed, 2cureX’s distributor in Slovenia, for IndiTreat® Sample Collection Sets.

The IndiTreat® Sample Collection Set contains all the elements used by IndiTreat® customers to store the patient tissue sample and preserve it through the transportation from the hospital to 2cureX labs in Copenhagen.

Hospitals need to get these Sample Collection Sets from the distributors in each country prior to scheduling the patient´s biopsy, therefore getting this first order is an important proof point that the process to start using IndiTreat® in hospitals has finally been set in motion. Recurrent orders are expected from this and other distributors as hospitals gradually integrate IndiTreat® to the portfolio of technologies used by their Oncologists.

With this achievement, 2cureX completes all the business goals it had announced for 2021, namely:

  • Getting ISO 13485 certification
  • Successful completion of the TICC trial in metastatic colorectal cancer (supported by EU MicroCaT project - H2020 no. 777718)
  • Launching two IndiTreat® tests – IndiTreat® Start and IndiTreat® Extend
  • Having distribution agreements covering 11 countries and 20% of European population
  • Assembling a new Advisory Board specialized in GI cancers
  • Launching an early access program – IGNITE – and enrolling the first hospitals to it
  • Getting the first IndiTreat® sales

Outstanding year for 2cureX

“This has been an outstanding year for 2cureX” said Fernando Andreu, CEO of 2cureX. “We have built a very solid foundation for our future expansion, at a speed that was only possible thanks to the exceptional commitment and dedication of our team, and our business and clinical partners. We are looking very much forward to an exciting 2022”.